{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T09:15:30Z","timestamp":1718788530825},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1097\/cpm.0b013e318272ce61","type":"journal-article","created":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T09:30:42Z","timestamp":1351762242000},"page":"282-288","source":"Crossref","is-referenced-by-count":3,"title":["Mesothelioma"],"prefix":"10.1097","volume":"19","author":[{"given":"Carmen M.","family":"Rosario","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Kamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210129","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1378\/chest.08-2665","article-title":"Malignant pleural mesothelioma: an update on biomarkers and treatment.","volume":"136","author":"Ray","year":"2009","journal-title":"Chest"},{"key":"R2-6-20210129","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.trsl.2009.01.004","article-title":"Asbestos-induced lung diseases: an update.","volume":"153","author":"Kamp","year":"2009","journal-title":"Transl Res"},{"key":"R3-6-20210129","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province.","volume":"17","author":"Wagner","year":"1960","journal-title":"Br J Ind Med"},{"key":"R4-6-20210129","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.mrrev.2008.02.002","article-title":"Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases.","volume":"659","author":"Neri","year":"2008","journal-title":"Mutat Res"},{"key":"R5-6-20210129","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses.","volume":"227","author":"Carbone","year":"2012","journal-title":"J Cell Physiol"},{"key":"R6-6-20210129","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1440-1843.2011.01975.x","article-title":"Asbestos use and asbestos-related diseases in Asia: past, present and future.","volume":"16","author":"Le","year":"2011","journal-title":"Respirology"},{"key":"R7-6-20210129","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1378\/chest.125.3.1103","article-title":"Asbestos and the pleura: a review.","volume":"125","author":"Cugell","year":"2004","journal-title":"Chest"},{"key":"R8-6-20210129","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1183\/09031936.98.12040972","article-title":"Malignant pleural mesothelioma.","volume":"12","author":"Boutin","year":"1998","journal-title":"Eur Respir J"},{"key":"R9-6-20210129","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.disamonth.2010.12.004","article-title":"Mesothelioma.","volume":"57","author":"Fuhrer","year":"2011","journal-title":"Dis Mon"},{"key":"R10-6-20210129","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2214\/ajr.172.4.10587144","article-title":"Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.","volume":"172","author":"Heelan","year":"1999","journal-title":"AJR Am J Roentgenol"},{"key":"R11-6-20210129","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1378\/chest.125.2.489","article-title":"Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging.","volume":"125","author":"Duysinx","year":"2004","journal-title":"Chest"},{"key":"R12-6-20210129","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma.","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur Respir J"},{"key":"R13-6-20210129","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5858\/arpa.2010-0604-RA","article-title":"Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.","volume":"136","author":"Betta","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"R14-6-20210129","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.humpath.2005.01.019","article-title":"D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma.","volume":"36","author":"Ordonez","year":"2005","journal-title":"Hum Pathol"},{"key":"R15-6-20210129","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/PAS.0b013e31814faacf","article-title":"Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin.","volume":"32","author":"Padgett","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R16-6-20210129","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2559.2005.02331.x","article-title":"Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data.","volume":"48","author":"King","year":"2006","journal-title":"Histopathology"},{"key":"R17-6-20210129","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s10147-011-0369-1","article-title":"Pathological and molecular biological approaches to early mesothelioma.","volume":"17","author":"Tsujimura","year":"2012","journal-title":"Int J Clin Oncol"},{"key":"R18-6-20210129","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/PAS.0b013e3181b6bde3","article-title":"Tenascin-X is a novel diagnostic marker of malignant mesothelioma.","volume":"33","author":"Yuan","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R19-6-20210129","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/dc.20556","article-title":"The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.","volume":"34","author":"Saad","year":"2006","journal-title":"Diagn Cytopathol"},{"key":"R20-6-20210129","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/PAT.0b013e32834642da","article-title":"Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma.","volume":"43","author":"Kao","year":"2011","journal-title":"Pathology"},{"key":"R21-6-20210129","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2559.2009.03322.x","article-title":"Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma.","volume":"55","author":"Amatya","year":"2009","journal-title":"Histopathology"},{"key":"R22-6-20210129","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.semtcvs.2009.06.005","article-title":"Pathologic evaluation of malignant pleural mesothelioma.","volume":"21","author":"Chirieac","year":"2009","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"R23-6-20210129","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.5858\/133.8.1317","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.","volume":"133","author":"Husain","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"R24-6-20210129","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MCP.0b013e32812144bb","article-title":"Biomarkers for mesothelioma.","volume":"13","author":"Scherpereel","year":"2007","journal-title":"Curr Opin Pulm Med"},{"key":"R25-6-20210129","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1164\/rccm.200511-1789OC","article-title":"Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.","volume":"173","author":"Scherpereel","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R26-6-20210129","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.rmed.2009.05.017","article-title":"Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.","volume":"104","author":"Luo","year":"2010","journal-title":"Respir Med"},{"key":"R27-6-20210129","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1164\/rccm.200907-1020OC","article-title":"Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.","volume":"181","author":"Hollevoet","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R28-6-20210129","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma.","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"key":"R29-6-20210129","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.200802-258OC","article-title":"Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.","volume":"178","author":"Park","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R30-6-20210129","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1440-1827.2006.02024.x","article-title":"Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.","volume":"56","author":"Maeda","year":"2006","journal-title":"Pathol Int"},{"key":"R31-6-20210129","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-06-0472","article-title":"Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.","volume":"12","author":"Onda","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R32-6-20210129","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/JTO.0b013e318180477b","article-title":"Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.","volume":"3","author":"Creaney","year":"2008","journal-title":"J Thorac Oncol"},{"key":"R33-6-20210129","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1164\/rccm.200807-1125OC","article-title":"Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.","volume":"179","author":"Grigoriu","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"R34-6-20210129","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1378\/chest.11-0129","article-title":"The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.","volume":"141","author":"Hollevoet","year":"2012","journal-title":"Chest"},{"key":"R35-6-20210129","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMoa051185","article-title":"Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.","volume":"353","author":"Pass","year":"2005","journal-title":"NEJM"},{"key":"R36-6-20210129","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1158\/1078-0432.CCR-08-0360","article-title":"Osteopontin levels in an asbestos-exposed population.","volume":"15","author":"Park","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R37-6-20210129","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-06-2144","article-title":"Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.","volume":"13","author":"Grigoriu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R38-6-20210129","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.rmed.2004.04.018","article-title":"High plasma concentrations of osteopontin in patients with interstitial pneumonia.","volume":"99","author":"Kadota","year":"2005","journal-title":"Respir Med"},{"key":"R39-6-20210129","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0021-9150(03)00298-3","article-title":"Plasma osteopontin levels are associated with the presence and extent of coronary artery disease.","volume":"170","author":"Ohmori","year":"2003","journal-title":"Atherosclerosis"},{"key":"R40-6-20210129","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ctrv.2011.01.001","article-title":"Advances in the biology of malignant pleural mesothelioma.","volume":"37","author":"Zucali","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"R41-6-20210129","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1002\/ijc.25285","article-title":"Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma.","volume":"127","author":"Gee","year":"2010","journal-title":"Int J Cancer"},{"key":"R42-6-20210129","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1165\/rcmb.2009-0060OC","article-title":"MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications.","volume":"42","author":"Busacca","year":"2010","journal-title":"Am J Respir Cell Mol Biol"}],"container-title":["Clinical Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CPM.0b013e318272ce61","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T19:19:11Z","timestamp":1643570351000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045413-201211000-00006"}},"subtitle":["Update on Diagnostic Strategies"],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/cpm.0b013e318272ce61","relation":{},"ISSN":["1068-0640"],"issn-type":[{"value":"1068-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}